Investigating The Impact of Catalase Gene Polymorphism Rs7943316 on Beta-Thalassemia Major Susceptibility in An Iraqi Patient
Article Sidebar
Main Article Content
Abstract
Beta-thalassemia major (β-TM) is a severe genetic blood disorder prevalent in regions including the Mediterranean, Middle East, and parts of Asia, marked by impaired synthesis of the beta-globin chain of hemoglobin. This leads to significant health complications such as chronic anemia, iron overload, and increased oxidative stress in patients. This study investigated the potential role of the rs7943316 polymorphism in the catalase gene in the pathophysiology of β-thalassemia major in Iraq. Between October 2023-January 2024, 105 blood samples were collected from 60 β-thalassemia patients on iron therapy for at least two years and 45 healthy controls. This study compared the demographic characteristics of the control and β-TM patients. The study found significant differences in hemoglobin and ferritin levels between the groups and significant variation in human catalase. Patients with β-TM exhibited elevated levels (225 ± 121 KU/L) compared to the control group (85.2 ± 18.6 KU/L), with a p-value of less than 0.0001. The study found no significant correlation between the rs7943316 polymorphism and an increased risk or severity of β-thalassemia in the studied population. Catalase serum levels were significantly higher in β-thalassemia patients than in controls, suggesting that this polymorphism does not significantly contribute to clinical variability or risk.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Iyevhobu KO, Okobi TJ, Usoro ER, Ivie AA, Ken-Iyevhobu BA, Victoria OO. Overview of beta-thalassemia. In: Thalassemia Syndromes – New Insights and Transfusion Modalities. IntechOpen; 2023.
Khalaf AA. Relationship of reproductive hormones and fertility in patients with beta-thalassemia major. J Chem. 2021;15:1–15.
Abdallah AMA. Thalassemia and pregnancy complications. World J Adv Res Rev. 2022;14(1):363–7.
Benz EJ, Angelucci E. Diagnosis of thalassemia (adults and children). UpToDate. 2022. Accessed September 10, 2022.
Traeger-Synodinos J, Vrettou C, Sofocleous C, Zurlo M, Finotti A, Gambari R. Impact of α-globin gene expression and α-globin modifiers on the phenotype of β-thalassemia and other hemoglobinopathies: implications for patient management. Int J Mol Sci. 2024;25(6):3400.
Lal A, et al. The transfusion management of beta thalassemia in the United States. Transfusion. 2021;61(10):3027.
Shash H. Non-transfusion-dependent thalassemia: a panoramic review. Medicina (B Aires). 2022;58(10):1496.
Subahi EA, et al. Extramedullary haematopoiesis in patients with transfusion-dependent β-thalassaemia: a systematic review. Ann Med. 2022;54(1):764–74.
Marchesani S, et al. The blood count as a compass to navigate in the ever-changing landscape of the carrier state of hemoglobinopathies: a single-center Italian experience. Front Pediatr. 2023;11:1228443.
Selvan V, DipABLM CCD, Piepkorn M, Robinson K. Maternal and neonatal outcomes in a cohort of COVID-positive mothers in West Texas population. American Academy of Family Physicians; 2023.
Tartaglione I, et al. Hearing loss in beta-thalassemia: systematic review. J Clin Med. 2021;11(1):102.
Ali S, et al. Current status of beta-thalassemia and its treatment strategies. Mol Genet Genomic Med. 2021;9(12):e1788.
Khan AM, Al-Sulaiti AM, Younes S, Yassin M, Zayed H. The spectrum of beta-thalassemia mutations in the 22 Arab countries: a systematic review. Expert Rev Hematol. 2021;14(1):109–22.
Azman NF, et al. Genetic polymorphisms of HbE/beta-thalassemia related to clinical presentation: implications for clinical diversity. Ann Hematol. 2020;99:729–35.
Baird DC, Batten SH, Sparks SK. Alpha- and beta-thalassemia: rapid evidence review. Am Fam Physician. 2022;105(3):272–80.
Saify K, Saadat I, Saadat M. Influence of A-21T and C-262T genetic polymorphisms at the promoter region of the catalase gene on gene expression. Environ Health Prev Med. 2016;21(5):382–6. doi:10.1007/s12199-016-0540-4.
Susanah S, et al. Iron status in newly diagnosed β-thalassemia major: high rate of iron overload due to erythropoiesis drive. Biomed Res Int. 2021;2021:5560319.
Saeed R, Shahid F, Haneef S. Frequency of high serum ferritin levels in beta-thalassemia major patients. Pak J Med Health Sci. 2020;14(3).
Shekhar HU. Comment on: oxidative stress and antioxidant status in beta-thalassemia heterozygotes. Rev Bras Hematol Hemoter. 2013;35(6):385–6. doi:10.5581/1516-8484.20130125.
Bou-Fakhredin R, De Franceschi L, Motta I, Eid AA, Taher AT, Cappellini MD. Redox balance in β-thalassemia and sickle cell disease: a love and hate relationship. Antioxidants. 2022;11(5). doi:10.3390/antiox11050967.
Hanan F, Nahla AM. Evaluation of oxidative stress and antioxidant status in beta-thalassemia major patients: a single-center study. Med J Cairo Univ. 2020;88:2147–55.
Skakir ZH, Lawi ZKK, Lateef GR. Investigation of catalase gene polymorphisms in patients with thalassemia in Hilla city. Biochem Cell Arch. 2019;19(1):2495–7.
Tripathi P, Agarwal S, Tewari S, Mandal K. Status of catalase, glutathione peroxidase, glutathione S-transferase, and myeloperoxidase gene polymorphisms in beta-thalassemia major patients to assess oxidative injury and its association with enzyme activities. J Pediatr Genet. 2022;11(3):198–212.
Yahouédéhou SCM A, et al. Sickle cell anemia: variants in the CYP2D6, CAT, and SLC14A1 genes are associated with improved hydroxyurea response. Front Pharmacol. 2020;11:553064.